Alterity Therapeutics Statistics
Want to see AU:ATH full AI Analyst Report?
Alterity Therapeutics (ATH) Stock Statistics & Valuation Metrics
Total Valuation
Alterity Therapeutics has a market cap or net worth of AUD 57.29M. The enterprise value is AUD 32.34M.
- Market Cap
- AUD 57.29M
- Enterprise Value
- AUD 32.34M
Share Statistics
Alterity Therapeutics has 229,150,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 229,150,850
- Owned by Insiders
- 0.10%
- Owned by Institutions
- ―
Financial Efficiency
Alterity Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -57.61%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.51
- Return on Invested Capital (ROIC)
- -57.61%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.13M
- Employee Count
- 11
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Alterity Therapeutics is -2.26. Alterity Therapeutics’s PEG ratio is 0.13.
- PE Ratio
- -2.26
- PS Ratio
- 0.00
- PB Ratio
- 1.27
- Price to FCF
- -42.53
- Price to Operating Cash Flow
- -4.11
- PEG Ratio
- 0.13
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 0 and earned -23.40M in profits. Earnings per share was -0.11.
- Revenue
- 0
- Gross Profit
- -115.54K
- Operating Income
- -28.42M
- Pretax Income
- -26.90M
- Net Income
- -23.40M
- EBITDA
- -28.30M
- Earnings Per Share (EPS)
- -0.11
Cash Flow
In the last 12 months, operating cash flow was -22.52M and capital expenditures 22.52M, giving a free cash flow of 0 billion.
- Operating Cash Flow
- -22.52M
- Free Cash Flow
- 0
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Alterity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.35%
- Earnings Yield
- -43.03%
Stock Price Statistics
- Beta
- 1.76
- 52-Week Price Change
- -50.00%
- 50-Day Moving Average
- 0.35
- 200-Day Moving Average
- 0.47
- Relative Strength Index (RSI)
- 39.52
- Average Volume (3m)
- 356.35K
Important Dates
Alterity Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Feb 25, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Alterity Therapeutics as a current ratio of 14.52, with Debt / Equity ratio of 0.45%
- Current Ratio
- 14.52
- Quick Ratio
- 14.52
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.31
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Alterity Therapeutics has paid -3.50M in taxes.
- Income Tax
- -3.50M
- Effective Tax Rate
- 0.13
Enterprise Valuation
Alterity Therapeutics EV to EBITDA ratio is -0.71, with an EV/FCF ratio of -14.97.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.71
- EV to Free Cash Flow
- -14.97
- EV to Operating Cash Flow
- -1.52
Balance Sheet
Alterity Therapeutics has AUD 37.32M in cash and marketable securities with AUD 193.47K in debt, giving a net cash position of AUD 37.12M billion.
- Cash & Marketable Securities
- AUD 37.32M
- Total Debt
- AUD 193.47K
- Net Cash
- AUD 37.12M
- Net Cash Per Share
- AUD 0.16
- Tangible Book Value Per Share
- AUD 0.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Alterity Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -16.21%
Scores
- Smart Score
- 5
- AI Score
- 42

